Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals

A. Imaz; J. M. Llibre; M. Mora; G. Mateo; A. Camacho; J. R. Blanco; A. Curran; J. R. Santos; E. Caballero; I. Bravo; F. Gaya; P. Domingo; A. Rivero; V. Falco; B. Clotet; E. Ribera

doi:10.1093/jac/dkq432

Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals

Journal of Antimicrobial Chemotherapy ◽

10.1093/jac/dkq432 ◽

2010 ◽

Vol 66 (2) ◽

pp. 358-362 ◽

Cited By ~ 14

Author(s):

A. Imaz ◽

J. M. Llibre ◽

M. Mora ◽

G. Mateo ◽

A. Camacho ◽

...

Keyword(s):

Reverse Transcriptase ◽

Salvage Therapy ◽

Nucleoside Reverse Transcriptase Inhibitor ◽

Transcriptase Inhibitor ◽

Multidrug Resistant ◽

Efficacy And Safety ◽

New Class ◽

New Generation ◽

Reverse Transcriptase Inhibitor ◽

Hiv 1

Download Full-text

Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals

Journal of Antimicrobial Chemotherapy ◽

10.1093/jac/dkr287 ◽

2011 ◽

Vol 66 (9) ◽

pp. 2194-2194 ◽

Cited By ~ 1

Author(s):

A. Imaz ◽

J. M. Llibre ◽

M. Mora ◽

G. Mateo ◽

A. Camacho ◽

...

Keyword(s):

Reverse Transcriptase ◽

Salvage Therapy ◽

Nucleoside Reverse Transcriptase Inhibitor ◽

Transcriptase Inhibitor ◽

Multidrug Resistant ◽

Efficacy And Safety ◽

New Class ◽

New Generation ◽

Reverse Transcriptase Inhibitor ◽

Hiv 1

Download Full-text

Efficacy and Safety of Lersivirine Versus Etravirine for the Treatment of HIV-1 Infection in Patients with Prior Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Use and Evidence of NNRTI Resistance: A Randomized Phase 2B Trial

HIV Clinical Trials ◽

10.1310/hct1505-209 ◽

2014 ◽

Vol 15 (5) ◽

pp. 209-217 ◽

Cited By ~ 1

Author(s):

Edwin DeJesus ◽

Gerd Fätkenheuer ◽

Catherine Orrell ◽

Cunshan Wang ◽

James Jones ◽

...

Keyword(s):

Reverse Transcriptase ◽

Nucleoside Reverse Transcriptase Inhibitor ◽

Transcriptase Inhibitor ◽

Efficacy And Safety ◽

Nnrti Resistance ◽

Reverse Transcriptase Inhibitor ◽

Hiv 1

Download Full-text

Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients

AIDS ◽

10.1097/00002030-200005050-00004 ◽

2000 ◽

Vol 14 (7) ◽

pp. 791-799 ◽

Cited By ~ 26

Author(s):

Nina Khanna ◽

Thomas Klimkait ◽

Veronique Schiffer ◽

Jose Irigoyen ◽

Amalio Telenti ◽

...

Keyword(s):

Protease Inhibitor ◽

Reverse Transcriptase ◽

Salvage Therapy ◽

Nucleoside Reverse Transcriptase Inhibitor ◽

Transcriptase Inhibitor ◽

Reverse Transcriptase Inhibitor ◽

Hiv 1

Download Full-text

Faculty Opinions recommendation of Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.12019956.13157054 ◽

2011 ◽

Author(s):

Mark Wainberg ◽

Dimitrios Coutsinos

Keyword(s):

Reverse Transcriptase ◽

Nucleoside Reverse Transcriptase Inhibitor ◽

Transcriptase Inhibitor ◽

Subtype C ◽

Low Level ◽

Acute Hiv ◽

Reverse Transcriptase Inhibitor ◽

Hiv 1

Download Full-text

A Nanoparticle-Encapsulated Non-Nucleoside Reverse-Transcriptase Inhibitor with Enhanced Anti-HIV-1 Activity and Prolonged Circulation Time in Plasma

Current Pharmaceutical Design ◽

10.2174/1381612820666141014125213 ◽

2014 ◽

Vol 21 (7) ◽

pp. 925-935 ◽

Cited By ~ 11

Author(s):

Wen Li ◽

Qian Wang ◽

Yuan Li ◽

Fei Yu ◽

Qi Liu ◽

...

Keyword(s):

Reverse Transcriptase ◽

Nucleoside Reverse Transcriptase Inhibitor ◽

Transcriptase Inhibitor ◽

Circulation Time ◽

Reverse Transcriptase Inhibitor ◽

Anti Hiv ◽

Hiv 1

Download Full-text

Virologic Outcome After Switching From a Nucleoside Reverse Transcriptase Inhibitor to Tenofovir in Patients With Undetectable HIV-1 RNA Plasma Level

JAIDS Journal of Acquired Immune Deficiency Syndromes ◽

10.1097/00126334-200407010-00016 ◽

2004 ◽

Vol 36 (3) ◽

pp. 876-878 ◽

Cited By ~ 1

Author(s):

Marc Wirden ◽

Anne Geneviève Marcelin ◽

Roland Tubiana ◽

Marc Antoine Valantin ◽

Jade Ghosn ◽

...

Keyword(s):

Plasma Level ◽

Reverse Transcriptase ◽

Nucleoside Reverse Transcriptase Inhibitor ◽

Transcriptase Inhibitor ◽

Reverse Transcriptase Inhibitor ◽

Hiv 1

Download Full-text

Rilpivirine, a Non-Nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1

Analogue-Based Drug Discovery II ◽

10.1002/9783527630035.ch17 ◽

2010 ◽

pp. 409-441

Author(s):

Jerome Guillemont ◽

Luc Geeraert ◽

Jan Heeres ◽

Paul J. Lewi

Keyword(s):

Reverse Transcriptase ◽

Nucleoside Reverse Transcriptase Inhibitor ◽

Transcriptase Inhibitor ◽

Reverse Transcriptase Inhibitor ◽

Hiv 1

Download Full-text

Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties

European Journal of Medicinal Chemistry ◽

10.1016/j.ejmech.2020.113051 ◽

2020 ◽

pp. 113051

Author(s):

Xiangyi Jiang ◽

Boshi Huang ◽

Fisayo A. Olotu ◽

Jing Li ◽

Dongwei Kang ◽

...

Keyword(s):

Reverse Transcriptase ◽

Nucleoside Reverse Transcriptase Inhibitor ◽

Binding Pocket ◽

Transcriptase Inhibitor ◽

Region I ◽

Reverse Transcriptase Inhibitor ◽

Hiv 1

Download Full-text

Combined Analysis of Two-Year Follow-Up from Two Open-Label Randomized Trials Comparing Efficacy of Three Nucleoside Reverse Transcriptase Inhibitor Backbones for Previously Untreated HIV-1 Infection: OzCombo 1 and 2

HIV Clinical Trials ◽

10.1310/k2u9-qc2v-1y3v-5dyf ◽

2003 ◽

Vol 4 (4) ◽

pp. 252-261 ◽

Cited By ~ 19

Author(s):

J Amin ◽

A. Moore ◽

A Carr ◽

M.A. French ◽

M Law ◽

...

Keyword(s):

Reverse Transcriptase ◽

Nucleoside Reverse Transcriptase Inhibitor ◽

Randomized Trials ◽

Transcriptase Inhibitor ◽

Open Label ◽

Combined Analysis ◽

Reverse Transcriptase Inhibitor ◽

Hiv 1

Download Full-text

Characterization of a Mutant HIV-1 Reverse Transcriptase Resistant to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-imidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150)

Antiviral Chemistry and Chemotherapy ◽

10.1177/095632029400500410 ◽

1994 ◽

Vol 5 (4) ◽

pp. 278-281

Author(s):

H. Samanta ◽

R. Rose ◽

A. K. Patick ◽

C. M. Bechtold ◽

J. Trimble ◽

...

Keyword(s):

Reverse Transcriptase ◽

Nucleoside Reverse Transcriptase Inhibitor ◽

Serial Passage ◽

Transcriptase Inhibitor ◽

Viral Resistance ◽

Resistant Virus ◽

Reverse Transcriptase Inhibitor ◽

Hiv 1

A virus strain resistant to R82150, a non-nucleoside reverse transcriptase (NNRT) inhibitor (tetrahydro-imidazo [4,5, 1- jk] [1,4] benzodiazepine-2(1 H)-thione), was isolated following serial passage of HIV-1 RF in CEM-SS cells. The virus is cross-resistant to another non-nucleoside reverse transcriptase inhibitor, TGG-II-23A [1,4-dimethyl-1-[5,5-dimethyl-2-oxazoionyl]-naphthalen-2-one), but remains susceptible to AZT, DDI, D4T and phosphonoformate (PFA). DNA sequencing of reverse transcriptase genes from resistant virus indicated that R82150 selects for amino acid alterations Y181C and V108I. In vitro mutagenized reverse transcriptase and recombinant HIV-1 (pNL4-3) carrying either of the mutations have been generated. Genotypic and phenotypic analyses identified V108I as an unreported R82150-associated mutation. Both reverse transcriptase and viral resistance assays indicated that the resistance conferred by the V108I mutation is 7-fold less than that conferred by Y181C.

Download Full-text